Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Monopar Therapeutics reported Q1 2026 results with a net loss of $3.9 million ($0.46 per share) and cash reserves of $137.5 million, sufficient to fund operations through December 2027. The company highlighted positive Phase 3 data for its lead asset ALXN1840 (tiomolibdate choline) in Wilson disease, demonstrating greater neurologic benefit versus standard of care, with presentations at major neurology and liver disease conferences.
Key figures
- Revenue
- 0
- Net loss
- 3900000
- Ga expenses
- 1738006
- Rd expenses
- 3487247
- Interest income
- 1332203
- Cash runway date
- December 31, 2027
- Cash and investments
- 137500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.